Filing summary
Entity and period: The supplied filing identifies the registrant as Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.). It is a Form 10-Q for the quarter ended December 31, 2012, covering the third quarter and first nine months of fiscal 2013. Amounts below are in U.S. dollars; financial statement amounts are in thousands unless stated otherwise.
Business context and financial performance
The company develops and sells healthcare products based primarily on its Microcyn technology, alongside nutritional products and laboratory testing services. It notes that it lacks U.S. regulatory approval to market Microcyn as a drug or as a medical device with antimicrobial or wound-healing indications.
| Metric | Three months ended Dec. 31, 2012 | Nine months ended Dec. 31, 2012 | Comparable 2011 period |
|---|---|---|---|
| Total revenue | $3.540 million | $12.117 million | $2.790 million / $9.393 million |
| Gross profit | $2.471 million | $8.555 million | $1.852 million / $6.579 million |
| Operating expenses | $3.151 million | $10.547 million | $4.206 million / $11.581 million |
| Loss from operations | $0.680 million | $1.992 million | $2.354 million / $5.002 million |
| Net loss | $1.912 million | $2.986 million | $2.547 million / $5.561 million |
| Basic and diluted loss per share | $0.05 | $0.12 | $0.09 / $0.21 |
Quarterly revenue rose 27% and nine-month revenue rose 29% year over year. Product revenue growth was driven mainly by the United States and Mexico, including new U.S. dermatology products and licensing revenue. Service revenue declined slightly. The company reported Microcyn product gross margins of 73% for the quarter and 74% for the nine months, versus 71% and 75%, respectively, a year earlier; Mexico margins were lower following the More Pharma distribution arrangement.
Cash flow, balance sheet, and financing
- Cash and cash equivalents were $6.598 million at December 31, 2012, up from $3.351 million at March 31, 2012. Working capital was $5.602 million.
- For the first nine months, operating cash flow was positive $2.194 million, investing cash flow was negative $0.254 million, and financing cash flow was positive $1.305 million. Operating cash flow benefited substantially from More Pharma upfront payments; it should not be read as recurring cash generation.
- Current assets were $10.900 million and current liabilities $5.298 million. Total liabilities were $8.702 million and stockholders’ equity was $3.128 million, compared with an equity deficiency of $0.868 million at March 31.
- Debt obligations were reported as $3.031 million outstanding before the described prepayments and discounts; the balance sheet carried current and long-term debt, net, of $1.558 million combined. The October lender transaction included issuance of 4.321 million shares valued at $3.5 million and changes to debt and warrant arrangements.
- The April 2012 registered direct offering generated $2.797 million net proceeds. The company also reported a $1.062 million deemed preferred-stock dividend for the nine-month period.
Material changes, outlook, and risks
- SG&A declined year over year, reflecting lower Mexico selling costs and lower stock compensation, partly offset by $410,000 of Mexico transition severance and other costs. Management expected SG&A to decline further as Mexico-related selling costs fell.
- Management expected R&D expense to increase slightly over the next few quarters for laboratory testing, clinical trials, and product development. No specific revenue or earnings guidance was provided.
- The company expected its cash to support working capital, sales and marketing, and R&D through at least January 1, 2014, but expected continuing losses and said additional financing might be needed. No new financing commitment was secured; without financing or a strategic partner, it could reduce costs and delay pivotal trials.
- A $5.1 million More Pharma upfront payment for Mexico licensing and distribution rights is being recognized over an estimated three-to-five-year period. More Pharma receivables were $1.306 million at quarter-end. Customer concentration was significant: three customers accounted for 64% of quarterly revenue, and one customer represented 43% of receivables.
- NASDAQ had determined the company met the stockholders’ equity listing requirement, but it had not regained compliance with the $1.00 minimum bid-price rule by the December 17, 2012 deadline. A hearing was scheduled for February 21, 2013; continued listing was not assured. The company said it might use a reverse split to address the deficiency.
- A strategic partner received an FDA warning letter concerning manufacturing and marketing of certain Microcyn-based products. The company was assessing potential impact; partner noncompliance could lead to product sales interruption or other regulatory action. The filing also describes a prior voluntary Class II labeling recall, which management said had nominal cost and no material revenue impact.
- After quarter-end, the company proposed spinning off its biotechnology business as Ruthigen and announced leadership changes. The spin-off was not assured. The CEO transition and Ruthigen arrangements are described as subsequent events.
Important facts for investors to verify
- Confirm the issuer: this source is an Oculus Innovative Sciences filing, despite the request metadata naming Sonoma Pharmaceuticals.
- Review the sustainability of cash flow and the cash runway, given reliance on the More Pharma upfront payment and management’s stated potential need for additional capital.
- Check debt repayment terms and the economic consequences of the lender share issuance, including any remaining share-sale, prepayment, or cash-shortfall provisions.
- Track the NASDAQ bid-price hearing and any reverse-split action, as well as the proposed Ruthigen spin-off and its terms.
- Assess the FDA warning-letter exposure, customer concentration, and collection of the $1.306 million More Pharma receivable.